Last updated 2026-09-06
- Acquired by Purple Biotech for $3.8M, Jan 2017
- Raised $1.6M Secondary led by Kitov Pharma, Oct 2017
- Raised $1M Undisclosed Round led by Orot Luces, Jun 2008
Total raised
$2.6M
Stage
Acquired
Founded
2005
Headcount
6
HQ
Herzliya, Israel
Sector
Drug Discovery
Website ↗Registrar ID: 514964055 (TyrNovo Ltd.)
About
TyrNovo is a company that develops small molecular drugs designed to treat cancer and inflammation diseases. Their drugs are used for the treatment of various neurodegenerative conditions resulting from acute events such as stroke, traumatic brain injury, nerve agent exposure, open heart surgery, and glaucoma. The company's novel approach promotes the degradation of insulin-receptor substrates 1 and 2, aiming to improve cancer therapy, prevent drug resistance, and increase life expectancy. TyrNovo's activity has been entirely integrated into Kitov Pharmaceuticals (now Purple Biotech Ltd.). TyrNovo was founded on the basis of research by Hebrew University Prof. Alexander Levitzki.
Funding history · 3 rounds · $2.6M total
3 events/rounds · $2.6M Total Funding: $2.6M in Private Equity
Oct 2017
Secondary
$1.6M
pitchbook.com
Mar 2013
Undisclosed Round
Undisclosed
pitchbook.com
Jun 2008
Undisclosed Round
$1.0M
pitchbook.com
Offices
Herzliya, Israel · HQ / main office
Q&A
- What is TyrNovo's primary focus?
- TyrNovo specializes in developing targeted therapies to prevent resistance to cancer drugs, aiming to improve cancer treatment and increase life expectancy.
- What is TyrNovo's core technological approach?
- TyrNovo's novel approach promotes the degradation of insulin-receptor substrates 1 and 2, activating the off switch to extensively block major oncogenic pathways in cancer treatment.
- Which compounds has TyrNovo licensed?
- TyrNovo has exclusively licensed compounds NT157 and NT219 from Yissum Research Development Company of the Hebrew University of Jerusalem.
- When was TyrNovo founded?
- TyrNovo was founded in September 2013.
- What is TyrNovo's current status?
- TyrNovo was acquired by Purple Biotech in January 2017 and is currently inactive.
- What is TyrNovo's primary sector classification?
- TyrNovo's primary sector is Health Tech & Life Sciences, specifically focusing on Pharma & Medical Biotechnology and Drugs Discovery & Development.
- Does TyrNovo hold any patents?
- Yes, TyrNovo holds one patent.
Team · 1
Dr. Hadas Reuveni
Founder · Founder and Chief Technology Officer
Highlights
1 Patents
Tags
cancerpersonalizationbiopharmaceuticaldrug-discoveryoncologypharma-companies
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | www.tyrnovo.co.il |
|---|
Identifiers & details
| Legal name | TyrNovo Ltd. |
|---|---|
| Founded | 2005 |
| Employees (exact) | 6 |
| Status reason | Acquired (Inactive) by Purple Biotech on Jan 2017 - closed due to acquisition |
Acquisitions & public offerings
Acquired by Purple Biotech 2017-01 $3.8M
Radar intelligence
Patents
| EPO | 3 |
|---|
Publications (Crossref)
| Works | 7 |
|---|
Web history (Wayback)
| Domain | tyrnovo.co.il |
|---|
Certificate / subdomain footprint
| Subdomains | 2 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 514964055 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2013-08-27 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | yes |
| Last annual report | 2022 |
| Active charges / liens | 0 |
| Registry events | 0 |
| Registered address | אופנהיימר 4 רחובות |